Abstract: Systems, methods, and apparatuses are provided for drift compensation for codewords in memory. A memory device comprises memory cells and circuitry configured to sense a codeword stored in the array of memory cells using a reference voltage and determine an amount by which to adjust the reference voltage used to sense the codeword based on an estimated weight of the original codeword, a mean of threshold voltage values of each memory cell of the sensed codeword, and a total quantity of memory cells of the sensed codeword. The circuitry can further be configured to adjust the reference voltage used to sense the codeword by the determined amount.

Abstract: Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Abstract: The present disclosure relates generally to methods and apparatus to control delivery of a sealant during an invasive procedure. Disclosed methods and apparatus control movement of a syringe to control injection of sealant stored therein. For example, disclosed methods and apparatus can displace the syringe body relative to the plunger as the syringe is withdrawn from the target site, rather than displacing the plunger relative to the syringe body, to thereby pressurize the sealant or inject the sealant in an amount proportional to a distance the syringe body is withdrawn. This reduces the variability in the amount of sealant delivered along the syringe withdrawal pathway. The disclosed methods and apparatus can increase precision in movement of a syringe, thereby increasing precision in sealant delivery.

Abstract: Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Abstract: Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Abstract: Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Abstract: Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Abstract: Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Abstract: Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Abstract: Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Abstract: A method for measuring radiotherapy doses on a subject undergoing radiotherapy or other treatments with ionizing radiations includes: electrically insulating the subject during the radiotherapy treatment; applying at least one electrode to the subject, or connected to an amplifier with a system for acquiring the signal outgoing from the amplifier; detecting, by means of the at least one electrode, the voltage pulse produced during the radiotherapy treatment and deriving from the ionization secondary electrons set into motion and/or by the loaded net charge induced in the subject; converting said voltage pulse into a value of charge induced by the treatment in the subject; and determining the dose of ionizing radiations received by the subject by a processing system which uses the above value of the induced charge, the energy spectrum of the incident beam and the contact surface of the incident beam on the subject.

Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.

Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.

Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.

Abstract: The present invention discloses a method for treating a subject suffering from intermittent claudication (IC) wherein said subject takes an effective dose of propionyl L-carnitine or a pharmaceutically acceptable salt thereof and also engaging in a concomitant physical training program. The method is particular effective for patients with intermittent claudication at class II of the Leriche-Fontaine's classification. The method provides a relief from peripheral arterial disease symptoms, as shown by claudication-limited exercise tolerance, while also improving quality of life.

Abstract: The use of acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is described for the preparation of a medicament useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which said symptoms are selected from the group consisting of pain, paraesthesia and hyperaesthesia, in which the acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.

Abstract: The use of acetyl L-carnitine, or one of its pharmaceutically acceptable salts, is described for the treatment of neu-ropathic pain in patients with type 2 diabetes not treated with insulin.

Abstract: Acetyl L-carnitine, or of one of its pharmaceutically acceptable salts, is useful for the prevention of painful peripheral neuropathy in patients suffering from type 2 diabetes, in which symptoms are pain, paraesthesia or hyperaesthesia. The acetyl L-carnitine is administered orally at a dose of at least 3 grams/day.

Abstract: Acetyl L-carnitine is used to treat neuropathic pain in patients with type 2 diabetes who are not treated with insulin.